Our Business Strategy
Founded on the basis of innovative science and entrepreneurial spirit, we aim to deliver the best therapies for patients whilst giving back to society and fuelling our growth.
Our focus
Novel technologies and exciting research that doesn’t breach ethical considerations
With a pipeline of specialty and primary care medicines, we aim to grow and develop our pipeline through R&D collaborations to deliver the next generation of patient-centric pharmaceuticals.
Focusing on delivering a diverse yet specialized pipeline integrated with our "drug portfolio" system, we aim to bring the advancements in patient-centered innovation to every area of medicine, but for now, our focus lies in the Cardiovascular, renal, and metabolic; Respiratory and Immunology; Perioperative Medicine; and Oncology areas. We strive to utilize the best facilities and technologies to accelerate drug discovery and development through partnerships and collaborations with other biopharmaceuticals/biotechnology companies and research institutions.
​
Our priorities lay in ensuring optimal outcomes, displaying innovation and forward-thinking ideas, decreasing mortality, patient safety, and considering the individuality of patients as well. The theory behind our company was to introduce medicines that morph themselves to be compatible and flexible to patients’ needs, reshaping innovative but accessible medicine.
​
Our vision for the business, as entrepreneurs, is to expand the reach of our company to a multidisciplinary business - combining areas of cardiology with marine biology, combining microbiology with epigenetics. The future is bright for patient-centric, tailored therapeutics. The market needs pioneers in the latest most futuristic emerging sectors, all while maintaining affordability. Biosimilars have begun to emerge into the pharmaceutical industry and with our portfolio of biosimilar selenoproteins, we are ready for our business to set an example for that.
MISSION
We are entering a newly emerging sector in the pharmaceutical industry: tailored regenerative medicine. Patients and consumers (hospitals/pharmacies) require accessible, low-cost, and highly effective products (medicine) alongside sustainability due to the current rising issue of pollution, climate change, and decline infinite resources. We aim to meet these demands using our innovative technologies and approaches
ADVANCING INNOVATIVE SCIENCE
Taking high-potential early stage projects to the next level to increase successful outcomes in each of the Phases I, II and III, AI and Data Science as well as other electro/computer science based technologies can be used to accelerate and efficiate the drug discovery and development process.